- Home
- Equipment
- usa massachusetts
- potential therapeutic
Show results for
Refine by
Potential Therapeutic Equipment Supplied In Usa Massachusetts
10 equipment items found
Manufactured by:Boston Pharmaceuticals based inCambridge, MASSACHUSETTS (USA)
BOS-704 is a ghrelin O-acyl transferase inhibitor with therapeutic potential for multiple ...
by:Neoclease based inBoston, MASSACHUSETTS (USA)
The focus on innovation extends to the creation of comprehensive nuclease libraries, ensuring a wide range of tools for various applications. The company aims to shift the paradigm in therapeutic development, moving towards potential curative solutions for genetic diseases. As Neoclease continues to advance its technology, it invites investors and collaborators ...
by:Verb Biotics based inBoston, MASSACHUSETTS (USA)
Yso5 is a discovery-stage program leveraging a specific keystone gut bacteria (undisclosed) to potentiate the effects of Immune Checkpoint Blockade (ICB) drugs. The field of cancer therapy has been revolutionized by the use of immunotherapy. The microbiome breakthrough science today paves the way for innovative biotherapies to potentiate the effectiveness of ...
Manufactured by:Sage Therapeutics based inCambridge, MASSACHUSETTS (USA)
The human brain is a network of billions of nerve cells, connected in complex electrical circuits to communicate. Brain health and function depend on these circuits. The flow of information among these circuits is managed by neural regulatory pathways including the GABA and NMDA receptors ...
by:Sumitomo Pharma Oncology, Inc. based inCambridge, MASSACHUSETTS (USA)
TP-3654 is an oral investigational inhibitor of PIM kinases, which has potential antitumor and anti-fibrotic effects through multiple pathways, including induction of ...
Manufactured by:MorphoSys AG based inPlanegg, GERMANY
Tulmimetostat is a second-generation EZH2 inhibitor that has been designed to achieve comprehensive target coverage through extended on-target residence time. EZH2 acts as an epigenetic writer and normally places one or more methyl groups on a histone protein, leading to the suppression of gene expression. Some cancers depend on an abnormal pattern of gene expression and re-direct EZH2 to genes ...
Manufactured by:Moderna, Inc. based inCambridge, MASSACHUSETTS (USA)
Our scientists are developing mRNA medicines to help prevent or treat ...
by:Valo Health, Inc. based inBoston, MASSACHUSETTS (USA)
Opal is the first end-to-end integrated drug discovery & development platform. Traditional, linear approaches to target discovery and drug development have created sub-optimized systems that are intrinsically disintegrated and ...
by:Aphios Corporation based inWoburn, MASSACHUSETTS (USA)
An alpha (α)-secretase modulator for ameliorating Alzheimer’s Disease pathophysiology and cognitive impairment with neuroprotection. Aphios is developing APH-1104, a more potent analog of Bryostatin-1, which is neuroprotective by α-secretase activation via novel PKC isoforms, down-regulation of pro-inflammatory and angiogenic processes and the substitution of β-amyloid for ...
Manufactured by:MorphoSys AG based inPlanegg, GERMANY
Tafasitamab (MOR208) is a humanized FC-modified CD19 targeting immunotherapy in clinical development for the treatment of B cell malignancies. CD19 is broadly expressed on the surface of B cells. It is therefore considered as a potential target for the treatment of B cell malignancies, such as non-Hodgkin’s lymphoma (NHL), including diffuse large B cell lymphoma (DLBCL), indolent lymphomas ...